News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Imago Biosciences Enrolls First Patient In Phase 1/2 Study Of IMG-7289 In Acute Myeloid Leukemia And Myelodysplastic Syndrome



11/9/2016 11:17:22 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

SAN CARLOS, Calif., Nov. 8, 2016 /PRNewswire/ -- Imago BioSciences, a clinical-stage pharmaceutical company developing novel anti-cancer therapies, announced today that the first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This study will assess the safety, pharmacokinetics, pharmacodynamics and anti-neoplastic activity of IMG-7289, an inhibitor of the epigenetic enzyme lysine-specific demethylase 1.   

"We are encouraged by the progress of this program.  This study will provide us with valuable data on the safety, biomarker effects and activity of this novel agent both alone and in combination with all-trans retinoic acid (ATRA)," said Hugh Young Rienhoff, Jr. M.D., Imago's Chief Executive Officer.  "In non-clinical models, IMG-7289 has demonstrated potent anti-tumor activity against neoplastic myeloid cells, especially AML cells. These effects were synergized in combination with ATRA."

In the Phase 1 portion of the trial, both dose-escalation and duration-extension cohorts will be utilized to evaluate IMG-7289 as a single agent; additionally, an IMG-7289 plus ATRA combination treatment regimen will be investigated.  Pending evaluations of safety and clinical benefit, patients will be eligible to enroll in a Phase 2 expansion arm to evaluate longer-term anti-tumor activity. The trial targets enrollment of approximately 30 patients and is being conducted at six sites.

About IMG-7289

IMG-7289 is a small molecule developed by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme shown to be vital in cancer stem cells, particularly malignant bone marrow cells.  In non-clinical studies, IMG-7289 demonstrated robust in vivo anti-tumor efficacy across a range of myeloid malignancies as a single agent and in combination with other chemotherapeutic agents.  IMG-7289 is an investigational agent currently being evaluated in an ongoing clinical trial (ClinicalTrials.gov Identifier: NCT02842827).  

About Imago BioSciences

Imago BioSciences is a clinical-stage, venture-backed pharmaceutical company focused on discovering and developing novel anti-cancer therapeutics.  These include a range of hematologic malignancies including AML, MDS and the myeloproliferative neoplasms. The company is based in California.    

Please see the website at www.imagobio.com for additional information.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imago-biosciences-enrolls-first-patient-in-phase-12-study-of-img-7289-in-acute-myeloid-leukemia-and-myelodysplastic-syndrome-300359030.html

SOURCE Imago BioSciences


Read at BioSpace.com


comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES